Ads
related to: merck s- GMP Retrovirus Services
cGMP-compliant & fully scalable
Viral vector manufacturing
- GMP QC Services
Viral Vector & Plasmid Assays
Quality, Sterility & Potency
- AAV Reference Standards
Essential AAV Reference Standards
Full & Empty Capsids of 6 Serotypes
- Cell Therapy Production
Cell Therapy Manufacturing Services
From Clinical To Commercial
- GMP Retrovirus Services
Search results
Merck shares maintain Outperform rating amid ongoing clinical trials By Investing.com
Investing.com· 5 days agoOn Tuesday, BMO Capital maintained its Outperform rating on Merck & Co. Inc. (NYSE:MRK), with a...
Summit Therapeutics, AstraZeneca And More From The Year’s Biggest Cancer Conference
Forbes· 4 days agoThe conference was a big one for Summit Therapeutics, which saw its stock price more than double...
Experimental mRNA vaccines gain steam with promising cancer trial results
Semafor via Yahoo News· 6 days agoMelanoma patients who received monthly mRNA vaccines and Merck’s Keytruda immunotherapy had lower...
Promising trial data for Moderna-Merck skin cancer vaccine sends stock rising
Quartz· 6 days agoModerna stock jumped nearly 4% on Tuesday after the the company announced positive data from an...
Moderna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma...
Benzinga via Yahoo Finance· 7 days agoThe study is evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy...
Moderna, Merck say vaccine improved survival in patients with deadly skin cancer
CNBC· 7 days agoModerna and Merck released more positive three-year data Monday on their experimental vaccine, given...
2 Dividend Stocks Billionaires Are Buying: Should You?
Motley Fool via Yahoo Finance· 3 days agoMerck currently has one of the best-selling therapies in the world in its portfolio. That is none...
Moderna, Merck shares rise as combined melanoma therapy shows improved survival rate By...
Investing.com· 7 days agoModerna (NASDAQ:MRNA) and Merck (MRK) have released new, more encouraging three-year data on their...
ASCO: After Keytruda, Merck builds 3-pronged cancer strategy starring Moderna-partnered vaccine
FierceBiotech· 7 days ago“We're undergoing a pretty substantial transformation from a strategy that was focusing on...
Promising Trial Results Show New Standards In Cancer Treatment And Diagnostics Are On The Horizon
Benzinga via Yahoo Finance· 6 days agoOn Monday, Moderna (NASDAQ: MRNA) and Merck & Co (NYSE: MRK) also reported durable efficiency of...